Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib
暂无分享,去创建一个
J. Blay | D. Lambrechts | R. Sciot | J. Šufliarský | M. Debiec‐Rychter | T. van Wezel | H. Gelderblom | P. Schöffski | A. Wozniak | B. Boeckx | J. Bovée | Elodie Modave | Che-Jui Lee | M. Debiec-Rychter
[1] Ville Mustonen,et al. The mutational signatures of formalin fixation on the human genome , 2021, Nature Communications.
[2] L. Mariani,et al. The activity of chemotherapy in inflammatory myofibroblastic tumour (IMT): a multicentre, European retrospective case series analysis. , 2020, The oncologist.
[3] Jae-Il Park,et al. Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex , 2020, Experimental & Molecular Medicine.
[4] Fanshuang Zhang,et al. Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK‐rearranged non‐small‐cell lung cancer , 2019, Cancer medicine.
[5] Pankaj Vats,et al. Refractory and metastatic infantile fibrosarcoma harboring LMNA–NTRK1 fusion shows complete and durable response to crizotinib , 2019, Cold Spring Harbor molecular case studies.
[6] A. Drilon,et al. NTRK fusion-positive cancers and TRK inhibitor therapy , 2018, Nature Reviews Clinical Oncology.
[7] C. Cole,et al. The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers , 2018, Nature Reviews Cancer.
[8] M. Fiorentino,et al. MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report12 , 2018, Translational oncology.
[9] M. Mino‐Kenudson,et al. ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients , 2018, Pharmacogenomics and personalized medicine.
[10] Nikolaus Schultz,et al. Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers , 2018, Clinical Cancer Research.
[11] J. Blay,et al. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. , 2018, The Lancet. Respiratory medicine.
[12] Ville Mustonen,et al. The repertoire of mutational signatures in human cancer , 2018, Nature.
[13] J. Woyach,et al. Inflammatory Myofibroblastic Tumor Driven by Novel NUMA1-ALK Fusion Responds to ALK Inhibition. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.
[14] Alex H. Wagner,et al. DGIdb 3.0: a redesign and expansion of the drug–gene interaction database , 2017, bioRxiv.
[15] X. Yi,et al. TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib. , 2018, Journal of thoracic disease.
[16] Gang Chen,et al. Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review , 2017, Thoracic cancer.
[17] Levi Garraway,et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.
[18] K. Ohashi,et al. Intraosseous inflammatory myofibroblastic tumor of the mandible with a novel ATIC-ALK fusion mutation: a case report , 2016, Diagnostic Pathology.
[19] V. Georgoulias,et al. Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non-Small-cell Lung Cancer. , 2016, Clinical lung cancer.
[20] C. Strahlendorf,et al. ETV6-NTRK3 Is Expressed in a Subset of ALK-Negative Inflammatory Myofibroblastic Tumors , 2016, The American journal of surgical pathology.
[21] Y. Oda,et al. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours , 2016, Histopathology.
[22] Peter Lichter,et al. Chromothripsis in cancer cells: An update , 2016, International journal of cancer.
[23] B. Taylor,et al. deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution , 2016, Genome Biology.
[24] C. Antonescu,et al. Molecular Characterization of Inflammatory Myofibroblastic Tumors With Frequent ALK and ROS1 Gene Fusions and Rare Novel RET Rearrangement , 2015, The American journal of surgical pathology.
[25] Julie R. Park,et al. ALK-Related Neuroblastic Tumor Susceptibility , 2015 .
[26] Pieter Wesseling,et al. DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly , 2014, Genome research.
[27] D. Mahadevan,et al. Novel mutations in a patient with ALK-rearranged lung cancer. , 2014, The New England journal of medicine.
[28] Xiao-bin Cui,et al. Recurrent inflammatory myofibroblastic tumors harboring PIK3CA and KIT mutations. , 2014, International journal of clinical and experimental pathology.
[29] P. Stephens,et al. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. , 2014, Cancer discovery.
[30] Sandro Santagata,et al. Chaperones as thermodynamic sensors of drug–target interactions reveal kinase inhibitor specificities in living cells , 2013, Nature Biotechnology.
[31] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[32] L. Liau,et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation , 2013, Nature Genetics.
[33] C. Couture,et al. Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[34] A. Skubitz,et al. Gene expression identifies heterogeneity of metastatic propensity in high‐grade soft tissue sarcomas , 2012, Cancer.
[35] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[36] Y. Yatabe,et al. A Screening Method for the ALK Fusion Gene in NSCLC , 2012, Front. Oncol..
[37] A. Iafrate,et al. Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers , 2012, Science Translational Medicine.
[38] Tatiana G. Kutateladze,et al. Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.
[39] G. Getz,et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.
[40] Wei Zheng,et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. , 2010, Cancer research.
[41] Y. Chung,et al. Copy number alterations and expression profiles of candidate genes in a pulmonary inflammatory myofibroblastic tumor. , 2010, Lung cancer.
[42] C. Perou,et al. Allele-specific copy number analysis of tumors , 2010, Proceedings of the National Academy of Sciences.
[43] P. Bork,et al. A method and server for predicting damaging missense mutations , 2010, Nature Methods.
[44] E. Campo,et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. , 2009, The American journal of pathology.
[45] J. Hornick,et al. Inflammatory myofibroblastic tumours: where are we now? , 2007, Journal of Clinical Pathology.
[46] K. Murphy,et al. RANBP2 and CLTC are involved in ALK rearrangements in inflammatory myofibroblastic tumors. , 2007, Cancer genetics and cytogenetics.
[47] Mitsutoshi Nakamura,et al. Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas , 2005, Laboratory Investigation.
[48] Tsuyoshi Saito,et al. p53 mutation and MDM2 amplification in inflammatory myofibroblastic tumours , 2003, Histopathology.
[49] M. Nadji,et al. Mapping of genetic deletions on the long arm of chromosome 22 in human pancreatic adenocarcinomas. , 2000, Anticancer Research.
[50] M. Merino,et al. Allelic loss on chromosome 22q in epithelioid sarcomas. , 1998, Human pathology.
[51] H. Kurahashi,et al. Frequent loss of heterozygosity at telomeric loci on 22q in sporadic colorectal cancers , 1995, International journal of cancer.
[52] R. West,et al. Nuclear beta-catenin in mesenchymal tumors , 2005, Modern Pathology.
[53] H. Bartsch,et al. International Agency for Research on Cancer. , 1969, WHO chronicle.